tetano
Editor, Senior Moderator
J Am Heart Assoc
. 2024 Mar 12:e032426.
doi: 10.1161/JAHA.123.032426. Online ahead of print. Influence of Preoperative COVID-19 Vaccination on Outcomes After Coronary Artery Bypass Grafting-A Propensity Score-Matched Analysis
Hyoung Woo Chang[SUP] 1 [/SUP], Soyeon Ahn[SUP] 2 [/SUP], Jun Sung Kim[SUP] 1 [/SUP], Hyun Jeong Han[SUP] 1 [/SUP], You Kyeong Park[SUP] 1 [/SUP], Kang Min Kim[SUP] 1 [/SUP], Sang Yoon Kim[SUP] 3 [/SUP], Joon Chul Jung[SUP] 1 [/SUP], Jae Hang Lee[SUP] 1 [/SUP], Dong Jung Kim[SUP] 1 [/SUP], Cheong Lim[SUP] 1 [/SUP], Kay-Hyun Park[SUP] 1 [/SUP]
Affiliations
Background: Reports of intravascular thrombosis and cardiac complications have raised concerns about the safety of COVID-19 vaccinations, particularly in patients with high cardiovascular risk. Herein, we aimed to analyze the impact of preoperative COVID-19 vaccination on outcomes after coronary artery bypass grafting (CABG).
Methods and results: Among 520 patients who underwent isolated CABG from 2020 to 2022, 481 patients (mean±SD age: 67±11 years, 86 women) whose COVID-19 vaccination status could be confirmed were included. A total of 249 patients who had not received any COVID-19 vaccine before CABG (never vaccinated group) and 214 patients who had completed primary vaccination (fully vaccinated group) were subjected to 1:1 propensity score matching, and 156 pairs of patients were matched. There was no significant difference in early mortality between the 2 groups after matching. After matching, overall survival (P=0.930) and major adverse cardiovascular and cerebrovascular event-free survival (P=0.636) did not differ between the 2 groups. One-year graft patency also did not differ significantly between the 2 groups; all patent grafts in 85/104 patients (82%) and 62/73 patients (85%) in the never vaccinated and fully vaccinated groups, respectively (P=0.685). Subgroup analysis showed equivalent overall and major adverse cardiovascular and cerebrovascular event-free survival among AstraZeneca and Pfizer vaccine recipients and between those with ≤30 days versus >30 days from vaccination to CABG.
Conclusions: Despite the very high cardiovascular risk for patients undergoing CABG, COVID-19 vaccination did not affect major outcomes after CABG. Therefore, there is no reason for patients with coronary artery disease requiring CABG to avoid preoperative COVID-19 vaccination.
Keywords: COVID‐19; COVID‐19 vaccines; coronary artery bypass; coronavirus.
. 2024 Mar 12:e032426.
doi: 10.1161/JAHA.123.032426. Online ahead of print. Influence of Preoperative COVID-19 Vaccination on Outcomes After Coronary Artery Bypass Grafting-A Propensity Score-Matched Analysis
Hyoung Woo Chang[SUP] 1 [/SUP], Soyeon Ahn[SUP] 2 [/SUP], Jun Sung Kim[SUP] 1 [/SUP], Hyun Jeong Han[SUP] 1 [/SUP], You Kyeong Park[SUP] 1 [/SUP], Kang Min Kim[SUP] 1 [/SUP], Sang Yoon Kim[SUP] 3 [/SUP], Joon Chul Jung[SUP] 1 [/SUP], Jae Hang Lee[SUP] 1 [/SUP], Dong Jung Kim[SUP] 1 [/SUP], Cheong Lim[SUP] 1 [/SUP], Kay-Hyun Park[SUP] 1 [/SUP]
Affiliations
- PMID: 38471836
- DOI: 10.1161/JAHA.123.032426
Background: Reports of intravascular thrombosis and cardiac complications have raised concerns about the safety of COVID-19 vaccinations, particularly in patients with high cardiovascular risk. Herein, we aimed to analyze the impact of preoperative COVID-19 vaccination on outcomes after coronary artery bypass grafting (CABG).
Methods and results: Among 520 patients who underwent isolated CABG from 2020 to 2022, 481 patients (mean±SD age: 67±11 years, 86 women) whose COVID-19 vaccination status could be confirmed were included. A total of 249 patients who had not received any COVID-19 vaccine before CABG (never vaccinated group) and 214 patients who had completed primary vaccination (fully vaccinated group) were subjected to 1:1 propensity score matching, and 156 pairs of patients were matched. There was no significant difference in early mortality between the 2 groups after matching. After matching, overall survival (P=0.930) and major adverse cardiovascular and cerebrovascular event-free survival (P=0.636) did not differ between the 2 groups. One-year graft patency also did not differ significantly between the 2 groups; all patent grafts in 85/104 patients (82%) and 62/73 patients (85%) in the never vaccinated and fully vaccinated groups, respectively (P=0.685). Subgroup analysis showed equivalent overall and major adverse cardiovascular and cerebrovascular event-free survival among AstraZeneca and Pfizer vaccine recipients and between those with ≤30 days versus >30 days from vaccination to CABG.
Conclusions: Despite the very high cardiovascular risk for patients undergoing CABG, COVID-19 vaccination did not affect major outcomes after CABG. Therefore, there is no reason for patients with coronary artery disease requiring CABG to avoid preoperative COVID-19 vaccination.
Keywords: COVID‐19; COVID‐19 vaccines; coronary artery bypass; coronavirus.